Improving treatment for acute myeloid leukemia using targeted immunotherapy
Optimizing the Efficacy and Safety of CD33-Targeted Immunotherapy for Acute Myeloid Leukemia and Other CD33+ Disorders
['FUNDING_OTHER'] · FRED HUTCHINSON CANCER CENTER · NIH-10906142
This study is looking at new ways to make immunotherapy better and safer for people with acute myeloid leukemia (AML) by developing special antibodies that target a protein called CD33, and it aims to help improve treatment results while protecting healthy cells.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | FRED HUTCHINSON CANCER CENTER (nih funded) |
| Locations | 1 site (SEATTLE, UNITED STATES) |
| Trial ID | NIH-10906142 on ClinicalTrials.gov |
What this research studies
This research focuses on enhancing the effectiveness and safety of immunotherapy that targets CD33, a protein found on certain blood cells, particularly in patients with acute myeloid leukemia (AML). The team is developing new human antibodies that can target different parts of the CD33 protein, aiming to improve treatment outcomes. They will conduct laboratory studies to test these new therapies, including a method that uses radiation to specifically attack cancer cells while minimizing harm to normal cells. The ultimate goal is to translate these findings into clinical applications that can benefit patients directly.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with acute myeloid leukemia or other conditions that express the CD33 protein.
Not a fit: Patients without CD33-positive disorders or those who have not been diagnosed with acute myeloid leukemia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective and safer treatment options for patients with acute myeloid leukemia and other related disorders.
How similar studies have performed: Previous research has shown promise in targeting CD33 for AML treatment, but this approach with new antibodies and radioimmunotherapy is relatively novel.
Where this research is happening
SEATTLE, UNITED STATES
- FRED HUTCHINSON CANCER CENTER — SEATTLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LASZLO, GEORGE S — FRED HUTCHINSON CANCER CENTER
- Study coordinator: LASZLO, GEORGE S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.